NCT06507553 - Study of Influenza Vaccines Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years of Age and 60 Years of Age and Older | Biotech Hunter

Enrollment

400

Participants

Timeline

Start Date

August 12, 2024

Primary Completion Date

March 4, 2025

Study Completion Date

March 4, 2025

Conditions

InfluenzaHealthy Volunteers

Interventions

BIOLOGICAL

Trivalent-Darwin influenza vaccine

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

BIOLOGICAL

Augment-Tasmania influenza vaccine

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

BIOLOGICAL

TIV-2X Darwin influenza vaccine

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

BIOLOGICAL

Trivalent-Tasmania influenza vaccine

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Trial Locations (10)

2019

Investigational Site Number : 0360002, Botany

2035

Investigational Site Number : 0360012, Maroubra

2100

Investigational Site Number : 0360010, Brookvale

2228

Investigational Site Number : 0360011, Miranda

3124

Investigational Site Number : 0360001, Melbourne

4068

Investigational Site Number : 0360013, Taringa

4222

Investigational Site Number : 0360003, Southport

4506

Investigational Site Number : 0360005, Morayfield

4556

Investigational Site Number : 0360004, Sippy Downs

5067

Investigational Site Number : 0360007, Adelaide

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY